Immunoglobulin A Nephropathy: A Review Authors: Sulaiman Aseem, Sijie Zheng Published: 2024 ABSTRACT AbstractImmunoglobulin A nephropathy is a primary glomerulopathy, with prevalence ranking highest in the Pacific region, followed closely by Europe, but rare in Africa. Although practice patterns likely have contributed to its prevalence, there are genetic and environmental factors that contribute as well. Management has evolved over the past decade, with recent rapid advances in diagnosis, prognosis, and therapies. This review summarizes the history, pathogenesis, and diagnosis of immunoglobulin A nephropathy and also cites relevant clinical trials, latest treatment options, and unanswered questions. History In 1968, Berger and Hinglais first described “immunofluorescence demonstrated deposits in the capillaries fixing the anti-[immunoglobulin A] serum” in renal biopsies of 25 patients. Among these 25 patients, the duration of “evolution of the nephropathy from its discovery until the biopsy” ranged from a few months to 12 years.1 Epidemiology Immunoglobulin A (IgA) nephropathy (IgAN) has been recognized as the most common primary glomerulonephritis (GN) worldwide, with an incidence of 20–30 per million person-year.2 IgAN occurs with higher frequency in Asian (45 per million person-year in Japan) and White populations (31 cases per million person-year in France) vs African countries.3 These disparities are partially due to varying practice patterns, including screening, biopsy, and referrals.3 In Japan, schoolchildren aged 6–15 years have undergone urinalysis since 1974, with IgAN being the most common primary GN diagnosed.4 Patients with hematuria in Hong Kong often are referred for renal biopsy after negative workup by urologists,5 although in the US, patients with hematuria with normal-to-mild decreased estimated glomerular filtration rate (eGFR) with a urine-to-creatinine ratio (UPCR) of < 1 g/d are commonly not biopsied; a practice which has likely led to misdiagnosed with presumed-IgAN. Some of these patients may have Alport syndrome (collagen type IV disease). In addition, a retrospective study (from March 1, 2001, to February 28, 2005) conducted in a large kidney biopsy center in the US showed that IgAN was the most common GN and the most common cause of end-stage kidney disease in young White adult, but rare in the Black population.6 In 510 renal transplantation (446 living donors, 64 cadaveric donors) donor allograft studies conducted in Japan, the incidence of mesangial IgA deposits was ~ 16%, suggesting IgAN is likely underdiagnosed.7 Clinical Presentation Hematuria is the hallmark of IgAN and often occurs during or a few days post–upper respiratory or gastrointestinal infection. Thus, it is termed “synpharyngitic” as opposed to post-infectious GN, the latter of which occurs a few weeks after an infection.8 Hematuria can accompany the disease with varying degrees of proteinuria and eGFR levels. Proteinuria is measured either by a 24-hour urine collection or, more practically, as the urine protein to urine creatinine ratio (UPCR). UPCR in chronic kidney disease (CKD) is divided into 3 categories based on the albumin-to-ceatinine ratio (in milligrams per gram): A1 (< 30 mg/g), A2 (30–300 mg/g), and A3 (> 300 mg/g). For IgAN, most patients present with hematuria, with proteinuria ranging from undetected to the subnephrotic range.9 Some can also have hypertension and various degrees of decreased kidney function, with a fewer percentage presenting as nephrotic syndromes and/or acute kidney injury. Coexisting podocytopathy is often present in the nephrotic syndrome group. Some patients present with acute kidney injury with a rapid decline of kidney function and with biopsy often showing crescent formation. Diagnosis Diagnosis of IgAN requires a kidney biopsy; however, many patients are considered as “presumed IgAN”, especially in Asian populations. Often patients with asymptomatic hematuria and low-grade proteinuria are not biopsied. This practice needs to change. Recent studies have shown that some of the patients with lower-grade proteinuria are at risk for progression of disease and may benefit from earlier treatment and closer monitoring. In addition, a subgroup of patients could have thin basement membrane nephropathy (recently reclassified into collagen type IV syndrome/Alport syndrome) and which has been shown to coexist with IgAN.10,11 In a kidney biopsy, light microscopy shows mesangial hypercellularity with various degrees of endothelial hypercellularity and/or segmental sclerosis ± crescent formation. Immunofluorescence staining depicts an IgA dominant or codominant pattern, electron microscopy shows mesangial or paramesangial immune complex deposition. The IgAN Working Group developed and validated the mesangial hypercellularity (M) endocapillary hypercellularity (E) segmental glomerulosclerosis (S) tubular atrophy/interstitial fibrosis (T) system, or MEST score.12,13 Later, either the absence or presence of crescent formation was added, creating the MEST-C score. Combining the MEST score and clinical data can provide early risk prediction in IgAN. The components of MEST in biopsy are part of the International IgAN Prediction Tool used at biopsy in conjunction with clinical features to give risk estimation. In kidney biopsies, IgA deposits can coexist with minimal change disease; they usually present as nephrotic syndrome responsive to steroid treatment. Crescent formation can also present in IgAN; therefore, the addition of the C score to the MEST score. The higher the percentage of crescent formation in the biopsy, the faster the progression of kidney disease. Prognosis There are several presenting clinical features that predict a high chance of progression: higher creatinine at presentation, hypertension, and degree of proteinuria. The higher the proteinuria, the greater the likelihood of progression. Reduction of proteinuria has been shown to improve the prognosis of IgAN.14 Patients with minimal proteinuria were traditionally considered low progressors and thus to have favorable long-term outcomes.15 However, a subgroup of these patients can progress to end-stage renal failure.5,16 A recent study from the UK National Registry of Rare Kidney Diseases has shown patients previously considered as being at low risk of progression (UPCR < 0.88 g/g) also had high rates of kidney failure.17 In that registry, 20% and 30% of patients developed kidney failure within 10 years with proteinuria levels of < 0.44 g/g and 0.44–0.88 g/g, respectively.17 Szeto et al studied 72 patients with low-grade proteinuria and hematuria in Hong Kong. After 7 years, 33% exhibited UPCR > 1 g/g, 26% developed hypertension, and 7% progressed toward impaired renal function. Only 14% had complete resolution of hematuria. The median time for progression from proteinuria (> l g/d) to renal impairment was found to be 84 months (range, 56–132). The authors therefore concluded that IgAN with hematuria and minimal proteinuria is also a progressive disease.5 Given that most IgA patients are young at the time of diagnosis, some of these patients will likely progress to end-stage kidney disease (ESKD) in the latter part of their lives. The new target of UPCR likely should be aiming at less than 0.5 g/g, or even lower. IgAN is not as benign a disease as it was considered in the past. Half of patients will develop ESKD within 30 years, and they have been shown to have a lower life expectancy compared to patients without.18,19 Nonetheless, a heterogeneity of IgAN progression does exist: from slow progressor to aggressive progressor. Furthermore, due to the side effects of traditional treatments for IgAN (steroids and other immunosuppressants), many physicians and patients are reluctant to treat IgAN aggressively after it is diagnosed. The International IgAN Prediction Tool can quantify chance of progression and inform shared decision-making with patients.20 It can be calculated online at QxMD.21 It has a prognostic value, but its use is not recommended in the determination of the probability of treatment response in a specific patient.20 Pathogenesis Currently, the 4-hits hypothesis is the most accepted pathogenesis model for IgAN: 1) production of galactose-deficient IgA1 (hinge region) in gut mucosa; 2) translocation of these galactose-deficient IgA1 from gut mucosa to blood, leading to the production of autoantibodies toward the galactose-deficient IgA; 3) formation of immune complexes (autoantibody + galactose-deficient IgA); and 4) deposition of these immune complexes in the mesangium of the kidneys leading to kidney damage22 (Figure). There are entities associated with IgA deposition in the mesangium (secondary IgA, cirrhosis, inflammatory bowel disease, infection, and others). How these secondary IgAN cases fit into the 4-hit hypothesis model in regard to disease pathogenesis is still unclear. Proposed pathogenesis of IgA and potential therapeutics targets (numbered stars 1, 2, and 3). Reproduced from Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2018;33(5):763–777. DOI: 10.1007/s00467-017-3699-z.23 Creative Commons Attribution (CC BY 4.0) License (https://creativecommons.org/licenses/by/4.0/legalcode.en). APRIL = A PRoliferation-Inducing Ligand; BAFF = B-cell activating factor; IgA = immunoglobulin A; IgAN = IgA nephropathy; TLR = Toll-like receptor. Genetics Genome-wide association studies have identified susceptible loci associated with IgAN. These loci have further been associated with each step of the 4-hit hypothesis of pathogenesis, including mucosal immunity, antigen presentation, adaptive immunity, and complement activation.24 A genome-wide association study of patients with biopsy-proven IgAN vs controls showed 30 risk loci contributing toward 11% of disease risk.25 Clinical Trials and Treatment Options Current treatment options are based on several landmark trials, mainly divided into 2 categories: supportive care (SC) and immunomodulation. Supportive Care Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy Trial The Supportive versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial is a prospective randomized controlled trial conducted in Germany comparing SC vs immunosuppression (IS) plus SC therapy in 162 patients with baseline proteinuria of ~ 1.5 g/d.26 The study had a 6-month run-in period of maximized SC [renin angiotensin aldosterone system (RAAS)] blockade to achieve a blood pressure of < 125/75 mmHg, dietary consult, smoking cessation, avoid nephrotoxins, and statin to achieve total cholesterol < 200 mg/dL). During the run-in period, 30% of patients were able to reach a UPCR of < 0.75 g/g per day. Among these, 12 patients had an increase in proteinuria of > 0.75 g/g and were included into the final cohort. This reminds clinicians that patients who received “adequate” SC can still develop disease progression. Close follow-up is needed in this population. After the run-in period, 81 patients recieved SC alone vs 81 patients with SC plus IS.26 After a 3-year follow-up, although IS did show a clear benefit in the reduction of proteinuria, this did not lead to a tangible difference in eGFR decline. Furthermore, the IS arm was associated with higher side effects (severe infection, glucose intolerance, and weight gain).26 A subsequent 10-year follow-up on this cohort further failed to establish a clear benefit in eGFR decline.27 Sodium–Glucose Cotransporter-2 Inhibitor (SGLT2i) The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial compared the effects of dapagliflozin vs placebo in patients with CKD, including 270 patients with IgAN.28 In an analysis of patients with IgAN in the trial, dapagliflozin reduced proteinuria compared with placebo.29 Dapagliflozin also slowed the decline of kidney function.29 Given its cardiovascular and kidney benefit, sodium–glucose cotransporter-2 inhibitors have become the commonly prescribed medication for patients with IgAN. The interpretation of this data does have 2 caveats: 1) the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial was not specifically designed for patients with IgAN, and 2) the placebo arm of patients with IgAN seemed to have a higher rate of eGFR decline compared with patients in other IgAN trials. Sparsentan A highly potent dual endothelin (ET) and angiotensin receptor antagonist (ARB), sparsentan can bind with either ET receptors or angiotensin receptors. A single molecule can only bind with either receptor at one time. The Food and Drug Administration (FDA) granted full approval for the treatment of primary IgAN. In the Efficacy and Safety of Sparsentan Versus Irbesartan in Patients With IgA Nephropathy (PROTECT) trial, 404 participants received sparsentan or irbesartan randomly in a 1:1 ratio.30 All patients received maximal SC and had proteinuria > 1 g/d.30 At 36 weeks, the patients in the sparsentan arm exhibited significantly lower levels of proteinuria compared to patients in the irbesartan arm.30 Furthermore, patients in the sparsentan arm had a statistically significant slower decline in eGFR compared to those in the irbesartan arm in chronic slope but not in total slope, after 2 years. Total slope, defined as including the initial 5 weeks of eGFR, was –2.9 in the sparsentan arm vs –3.9 in the irbesartan arm (P = 0.058). The chronic slope, excluding the initial 5 weeks, was –2.7 in the sparsentan arm compared to –3.8 in the irbesartan arm (P = 0.037).30 The authors concluded that the sparsentan treatment reduced proteinuria and preserved kidney function.30 The initial decline in eGFR is not a new phenomenon, it has been consistently observed in most kidney protective trials. In the long term, eGFR stabilizes despite the initial decline. Immunosuppression Pozzi Protocol Pozzi et al studied 86 patients in Italy diagnosed with IgAN with urine protein excretion of 1.0–3.5 g daily and plasma creatinine concentrations of ≤ 1.5 mg/dL between 1987 and 1995. Patients were assigned supportive therapy vs steroid treatment randomly. All patients in both groups received RAAS blockade, blood pressure medications, and antiplatelet medications if needed. At the 5-year follow-up, steroids were shown to slow deterioration in renal function with few adverse effects.31 A follow-up study of this cohort showed 10-year renal survival rates were higher in the steroid group.32 The Pozzi protocol has been the classic treatment for patients with IgAN, and it was recommended in the global practice guideline. Subsequent studies have confirmed the benefit of steroids in preventing the progression of renal disease IgAN,33,34 until the STOP-IgAN trial. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study was a double-blind study of 503 patients with IgAN. Patients had an eGFR of between 20 and 120 mL/min and > 1 g proteinuria per day. They were randomly assigned to placebo vs methylprednisolone in a 1:1 fashion. The composite outcome was decline in eGFR, ESKD, and death because of kidney disease. After at least 3 months of SC (including RAAS blockade), patients received oral methylprednisolone or placebo for 6–9 months. Begun in 2012, and after recruiting 262 patients, the study was stopped by the Data Safety Monitor Board in 2015 due to a higher rate of infection in the steroid arm.35 Recruitment resumed in 2017 with half of the steroid dosage. Pneumocystis jirovecii pneumonia prophylaxis was added and the low cutoff of eGFR was increased to 30 mL/min. An additional 241 patients were enrolled into the trial.36 Methylprednisolone was found to reduce the rate of the composite outcome. The adverse effect of the reduced dose of methylprednisolone was comparable with placebo.36 It should be noted that after stopping the steroid, proteinuria levels in patients increased to baseline levels.36 Characteristic differences do exist between the patient populations of the STOP-IgAN and TESTING trials that could explain the variances in outcome. STOP-IgAN was conducted solely with European patients and the TESTING trial was conducted mostly with Asian patients. Whether this suggests Asian patients may have a different disease prognosis than European patients is unclear. Another major difference was that the baseline UPCR in STOP-IgA was ~ 1 but the TESTING trial it was ~ 2. Hydroxychloroquine Sixty patients with IgAN in China were randomized to either hydroxychloroquine or placebo for 6 months. Neither the investigators nor participants knew what they were getting.37 At the end of the study period, hydroxychloroquine significantly lowered the proteinuria compared with results seen in the placebo group.37 Mycophenolate In Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy (The MAIN Trial), Fan Fan Hou et al conducted a randomized clinical trial with 238 patients with IgAN in China.38 Participants had proteinuria > 1 g/d and eGFR > 30 and < 60 mL/min/1.73 m2. Patients received SC, including losartan. After a 3-month run-in period, 170 patients (UPCR ≥ 0.75) enrolled into the study for 3 years: 85 patients received mycophenolate mofetil (MMF) with SC vs 85 who received SC alone. There were 2 primary outcomes: 1) doubling of creatinine plus ESKD plus death from kidney or cardiovascular etiologies, and 2) progression of CKD. The study found that MMF reduced the chance of disease progression. Interestingly, after discontinuation of MMF the annual decrease of eGFR increased.38 The Kidney Disease: Improving Global Outcomes guidelines thus recommend the consideration of MMF as a steroid-sparing agent for Chinese patients. Nefecon Nefecon (targeted released budesonide) is a special formulation of budesonide that acts locally at Peyer’s patches, where galactose-deficient IgA is primary produced.39 A small amount of budesonide is released systemically. Thus, theoretically it has more targeted effects locally and less systemic side effects. Patients with IgAN were randomized 1:1 with either nefecon or placebo for 9 months. Baseline eGFR was between 35 and 90 mL/min and UPCR was ≥ 0.8 g/g.40 After 9 months of treatment, patients were followed for 15 months. All patients (364) received optimized RAAS blockade. Results showed the nefecon group had an annual eGFR decline of 2.47 mL/min vs the decline in the control group of 7.52 mL/min.40 This led to full FDA approval of nefecon for IgAN. There was an initial increase of eGFR in the nefecon arm; however, afterward the rate of decline in eGFR was similar in both groups. This effect was also observed in the TESTING trial. The authors measured urinary creatinine excretion and reported no change in the nefecon group.41 However, like the TESTING trial, 2–3 years after stopping the nefecon, proteinuria levels increased to close to those of the placebo group again. This raised the question of how long the IS regimen should continue or whether a maintenance regimen with SC needs to be implemented. Emerging Therapies There are many new medications in the pipeline of development for IgAN, including complement pathway inhibitors, B-cell inhibitors, proteasome inhibitors, tyrosine kinase inhibitors, and other ET receptor antagonists.42 The FDA has just granted an accelerated approval for iptacopan (a factor B inhibitor of the alternative complement pathway) for proteinuria reduction in patients with IgAN. This is based on the Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study, a phase III study by Dana V Rizk et al, showing significant proteinuria reduction.43 Cost of Medication Recent investment interest from pharmaceutical companies in IgAN therapies is partly incentivized by clinical trials using albuminuria and eGFR slope as end points.44 There is a plethora of new medications for IgAN in various stages of their respective pipelines. This is great news for patients with IgAN; however, patients with kidney disease must also consider the cost of these medications. Unanswered Questions Given recent rapid advances in understanding of the pathophysiology, progression, and treatment options of IgAN, many new questions have emerged with respect to IgAN management. First, is IgAN a homogenous disease across different ethnic groups? Given a different rate of progression and response to treatment, it is likely a heterogenous disease due to different genetic predispositions and environmental triggers. What are these triggering factors? Diet or other environmental exposures needs to be delineated. Second, is the current approach of up-front conservative management with RAAS blockade, cholesterol control, and endothelium antagonists masking the subclinical inflammation of IgAN? Since it is an immune-mediated disease, using nonimmunological therapies at the initiation of the disease process may miss the opportunity of targeting the root cause of IgAN. In the past, the only immunotherapy available was a systemic steroid, which had many side effects, therefore supportive management alone for the slower progressor was a reasonable choice. Now with the availability of targeted therapy with fewer side effects, should we start with immunotherapy as initial treatment together with SC? Cost is currently a major barrier for this approach. Third, should we biopsy and perform genetic tests in most patients with hematuria regardless of the degree of proteinuria? We might be able to better understand the disease progression with this approach and find many “presumed IgAN” cases, especially in Asian and Hispanic populations, where their conditions could be other diseases. We could find some very active disease process in some of the patients. Fourth, what is the maintenance therapy for patients with IgAN who got IS? Both TESTING and nefecon trials have demonstrated relapse of proteinuria after stopping treatments. Should maintenance therapies for patients with IgAN be established to prevent progression? Finally, we are fortunate in this new era of many choices compared to the past few decades. However, with the emergence of new therapies, how does one risk stratify individuals to determine which patient should receive which therapy or therapies and at what sequence and combination? Conclusion We are in an exciting time of understanding and treating IgAN. New knowledge and therapies are emerging rapidly. Understanding the disease process and mastering these novel treatments will greatly benefit patients with IgAN.